FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

스택 라이브러리

Mitochondrial Renewal

Anti-Aging & Longevityadvanced

82

상호작용

82
Share
펩타이드

3

일 평균 mcg

550,000

수준

advanced

추가됨

May 17, 2026

개요

The Mitochondrial Renewal stack targets the organelles responsible for 90% of cellular energy production — mitochondria — whose dysfunction is now recognized as a central driver of aging and age-related disease. SS-31 (Elamipretide, also known as Bendavia) is a cell-penetrating tetrapeptide that concentrates 1000-5000x in the inner mitochondrial membrane, where it binds cardiolipin. Cardiolipin is essential for electron transport chain complex organization, and its oxidation with age leads to respiratory chain inefficiency, ROS overproduction, and energy failure. SS-31 stabilizes cardiolipin, restoring electron transport efficiency and reducing oxidative damage at its source. It has completed Phase 3 trials for Barth syndrome and Phase 2 for heart failure. MOTS-c is a mitochondrial-derived peptide (MDP) encoded within the mitochondrial genome''s 12S rRNA gene. It acts as a retrograde signal from mitochondria to the nucleus, activating AMPK (the cellular energy sensor) and promoting metabolic homeostasis. MOTS-c enhances glucose uptake independent of insulin, promotes fatty acid oxidation, and improves exercise capacity. In mouse studies, MOTS-c administration reversed age-related metabolic decline and improved physical performance in old animals to near-youthful levels. NMN (Nicotinamide Mononucleotide) is a direct precursor to NAD+, the essential coenzyme for mitochondrial function, DNA repair (via sirtuins and PARPs), and hundreds of metabolic reactions. NAD+ levels decline approximately 50% between ages 40-60, contributing to mitochondrial dysfunction, impaired DNA repair, and metabolic dysregulation. While NMN is technically a supplement rather than a peptide, its inclusion in this stack reflects the reality that mitochondrial restoration requires adequate NAD+ substrate alongside structural (SS-31) and signaling (MOTS-c) interventions. This is an experimental cutting-edge protocol targeting the fundamental bioenergetic decline of aging.

용량 프로토콜

SS-31 (Elamipretide)

Every day· subcutaneous

SS-31 (Elamipretide)에 대한 자세한 내용 →

40,000 mcg

1회 용량당

MOTS-c

3x/week· subcutaneous

MOTS-c에 대한 자세한 내용 →

10,000 mcg

1회 용량당

NAD+ precursor (NMN)

Every day· oral

NAD+ precursor (NMN)에 대한 자세한 내용 →

500,000 mcg

1회 용량당

목표 및 증거

Mitochondrial functionEnergyCellular healthExercise capacityAging
증거 등급:인체 RCT

경고

  • SS-31 completed Phase 3 for Barth syndrome. MOTS-c has limited human data. NMN is a supplement (not a peptide). This is an experimental combination.

Comments

Sign in to join the discussion

주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.